About this program

IPH5401 is a first-in-class therapeutic antibody that specifically binds and blocks C5a receptors (C5aR) expressed on subsets of myeloid-derived suppressor cells (MDSC) and neutrophils. Part of the innate immune system, these types of cells promote tumor growth by secreting inflammatory and angiogenic factors. They potently suppress T and NK cells and hamper the activities of PD-1 checkpoint blockers.

C5a, a factor in the complement cascade, is often overexpressed in tumors, where it attracts and activates MDSC and neutrophils in the tumor microenvironment. 

IPH5401 is a fully human antibody that blocks the binding of C5a to C5aR, thereby reducing the accumulation and activation of MDSC and neutrophils in tumors. Treatment with IPH5401 may unleash anti-tumor activities of T cells and NK cells. Preclinical experiments support development of IPH5401 as single agent and in combination with PD-1 checkpoint blockers or other cancer immunotherapies.

Innate Pharma acquired full worldwide exclusive rights to develop and commercialize the anti-C5aR antibody from Novo Nordisk A/S in July 2017.

Mechanism of action of IPH5401

 

In January 2018, Innate Pharma and AstraZeneca/MedImmune entered into a clinical trial collaboration to evaluate the safety and efficacy of the combination of IPH5401 and durvalumab (anti-PD-L1) in a Phase I/II study for patients with selected solid tumors (NSCLC and HCC) based on C5aR expression. The trial, called Stellar-001, is expected to start in the second half of 2018.

The Phase I part of the trial is expected to establish a recommended dose regimen of IPH5401 in combination with durvalumab in selected solid tumors, and the Phase II part will assess the safety and efficacy of the combination in patients with NSCLC or HCC (about 40 patients per indication).

The Anti-C5aR had a favorable safety profile in single & multi-dose, placebo controlled Phase I trials in rheumatoid arthritis led by Novo Nordisk A/S.